ARUP Announces New CMO Effective January 1, 2017: Dr. Julio C. Delgado

November 30, 2016

ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced the appointment of Julio C. Delgado, MD, MS, as chief medical officer (CMO), director of laboratories, and co-chief of the Clinical Pathology Division effective January 1, 2017. Delgado’s appointment fills a vacancy left by the departure of Jerry Hussong, MD, DDS.

“We are fortunate to have Julio join our executive team. During his time at ARUP, Julio has been instrumental in driving ARUP’s innovation and commitment to patient care. Based on his collaborative leadership style and knowledge of healthcare, we are confident that he will contribute to our success in this rapidly changing healthcare environment,” said Edgar Braendle, MD, president and CEO of ARUP.

Delgado joined ARUP Laboratories in 2006 as a medical director in the Department of Immunology. He served as co-executive director of the ARUP Institute for Clinical and Experimental Pathology® from 2013 to 2015. Delgado is an associate professor of pathology at the University of Utah School of Medicine. He received his MD from Universidad Industrial de Santander in Colombia and his MS degree in epidemiology from the Harvard School of Public Health, completing both his clinical residency training in clinical pathology and his research fellowship in immunology at the Harvard Medical School.

We are fortunate to have Dr. Delgado join our executive team. He’s been instrumental in driving ARUP’s innovation and commitment to patient care. Based on his collaborative leadership style and knowledge of healthcare, we are confident that he will contribute to our success in this rapidly changing healthcare environment.

Edgar Braendle, MD, president and CEO of ARUP

He is board certified in clinical pathology and histocompatibility laboratory testing by the American Board of Pathology and the American Board of Histocompatibility and Immunogenetics.

“I’m excited to take on this new opportunity and continue the important role of providing actionable, accurate, cost-efficient, and clear laboratory results that help physicians manage patient diseases and tailor treatment,” said Delgado. “With my academic medical background, I’m interested in preserving and strengthening ARUP's reputation as the premiere academic reference laboratory in the country.”

Hussong is leaving ARUP to pursue a new opportunity in the laboratory industry.

“Since joining ARUP in 2012, Jerry has worked tirelessly in promoting continuous quality improvement in our clinical operations. He has been an outstanding representative of ARUP with clients, prospective clients, professional organizations, and regulatory agencies. Jerry will be missed, and we wish him success in the next phase of his career,” said Braendle.